SCHEMBL297350

SCHEMBL297350

O=C(c1cccc(NS(=O)(=O)c2cccnc2)c1)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.51
PIK3CA P42336 2/20 0.45
BTK Q06187 1/20 0.45
CCR9 P51686 1/20 0.45
KMT2A Q03164 1/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 1/20 0.44
BRAF P15056 3/20 0.44
BRD4 O60885 1/20 0.44
GAA P10253 1/20 0.44
TBXA2R P21731 1/20 0.43
TBXAS1 P24557 1/20 0.43
MAP2K4 P45985 2/20 0.43
MAP2K7 O14733 1/20 0.43
PKM P14618 1/20 0.43
NAMPT P43490 1/20 0.43
BMPR1B O00238 1/20 0.42
PLK4 O00444 1/20 0.42
PIR O00625 1/20 0.42
AURKA O14965 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3709466 0.90 PGR (0.50) CYP3A4PIK3CABTKKMT2ACYP2C9
SCHEMBL298808 0.89 CYP3A4 (0.49) CYP3A4PIK3CABTKKMT2ACYP2C9
SCHEMBL299508 0.89 CYP3A4 (0.53) CYP3A4PIK3CABTKKMT2ACYP2C9
SCHEMBL298357 0.89 CYP3A4 (0.52) CYP3A4PIK3CABTKKMT2ACYP2C9
SCHEMBL298085 0.89 CYP19A1 (0.49) CYP3A4PIK3CABTKCCR9KMT2A
SCHEMBL3710534 0.88 CYP3A4 (0.57) CYP3A4PIK3CABTKCYP2C9CYP2C19
SCHEMBL298568 0.86 GAA (0.49) CYP3A4PIK3CABTKKMT2ABRD4
SCHEMBL298104 0.86 CYP2C9 (0.53) CYP3A4PIK3CABTKKMT2ACYP2C9
SCHEMBL299448 0.85 PIK3CA (0.52) CYP3A4PIK3CABTKBRD4MAP2K4
SCHEMBL297843 0.85 GAA (0.48) CYP3A4KMT2ACYP2C9CYP2C19BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP3A4 3611/4885PIK3CA 277/4885BTK 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.